REPYY vs. ELVN

Last updated Jun 4, 2026

REPYY (Repsol SA) and ELVN (Enliven Therapeutics Inc.) are both stocks. REPYY operates in Oil & Gas Integrated (Energy), while ELVN operates in Biotechnology (Healthcare). Over the past 5 years, REPYY returned 21.37%/yr vs 2.00%/yr for ELVN. At a 0.10 correlation, their price movements are largely independent.

Performance

REPYY vs. ELVN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Repsol SA (REPYY) and Enliven Therapeutics Inc. (ELVN). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, REPYY achieves a 49.15% return, which is significantly lower than ELVN's 133.96% return.

REPYY

• 1D: 1.46%
• 1M: 0.80%
• YTD: 49.15%
• 6M: 45.64%
• 1Y: 110.63%
• 3Y*: 31.86%
• 5Y*: 21.37%
• 10Y*: 14.09%

ELVN

• 1D: 1.44%
• 1M: -13.41%
• YTD: 133.96%
• 6M: 71.57%
• 1Y: 64.82%
• 3Y*: 18.69%
• 5Y*: 2.00%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

REPYY vs. ELVN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
REPYY Repsol SA	49.15%	66.69%	-13.03%	-2.01%	41.58%	20.97%	36.06%
ELVN Enliven Therapeutics Inc.	133.96%	-31.56%	62.57%	-15.40%	81.78%	-89.80%	47.00%

Correlation

The correlation between REPYY and ELVN is -0.05, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.05
Correlation (3Y) Calculated over the trailing 3-year period	0.07
Correlation (5Y) Calculated over the trailing 5-year period	0.09
Correlation (All Time) Calculated using the full available price history since Mar 13, 2020	0.10

The correlation between REPYY and ELVN shifts across timeframes, from -0.05 (1 year) to 0.10 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap REPYY : $30.61B ELVN : $2.26B
EPS REPYY : $2.16 ELVN : -$1.69
PB Ratio REPYY : 1.17 ELVN : 4.99
Total Revenue (TTM) REPYY : $55.91B ELVN : $0.00
Gross Profit (TTM) REPYY : $10.82B ELVN : -$46.00K
EBITDA (TTM) REPYY : $6.32B ELVN : -$110.65M

Return for Risk

REPYY vs. ELVN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

REPYY

REPYY Risk / Return Rank: 95
REPYY Sharpe Ratio Rank: 97
REPYY Sortino Ratio Rank: 95
REPYY Omega Ratio Rank: 95
REPYY Calmar Ratio Rank: 94
REPYY Martin Ratio Rank: 96

ELVN

ELVN Risk / Return Rank: 71
ELVN Sharpe Ratio Rank: 67
ELVN Sortino Ratio Rank: 74
ELVN Omega Ratio Rank: 69
ELVN Calmar Ratio Rank: 72
ELVN Martin Ratio Rank: 74

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

REPYY vs. ELVN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Repsol SA (REPYY) and Enliven Therapeutics Inc. (ELVN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	REPYY	ELVN	Difference
Sharpe ratio Return per unit of total volatility	3.81	0.80	+3.00
Sortino ratio Return per unit of downside risk	4.03	1.94	+2.09
Omega ratio Gain probability vs. loss probability	1.57	1.22	+0.36
Calmar ratio Return relative to maximum drawdown	6.43	1.77	+4.66
Martin ratio Return relative to average drawdown	21.36	4.61	+16.74
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

REPYY vs. ELVN - Sharpe Ratio Comparison

The current REPYY Sharpe Ratio is 3.81, which is higher than the ELVN Sharpe Ratio of 0.80. The chart below compares the historical Sharpe Ratios of REPYY and ELVN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	REPYY	ELVN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.81	0.80	+3.00
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.75	0.02	+0.73
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.44	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.46	-0.09	+0.55

Drawdowns

REPYY vs. ELVN - Drawdown Comparison

The maximum REPYY drawdown since its inception was -65.56%, smaller than the maximum ELVN drawdown of -98.20%. Use the drawdown chart below to compare losses from any high point for REPYY and ELVN.

Drawdown Indicators

	REPYY	ELVN	Difference
Max Drawdown Largest peak-to-trough decline	-65.56%	-98.20%	+32.64%
Max Drawdown (1Y) Largest decline over 1 year	-17.30%	-36.84%	+19.54%
Max Drawdown (3Y) Largest decline over 3 years	-34.63%	-56.05%	+21.42%
Max Drawdown (5Y) Largest decline over 5 years	-35.71%	-89.05%	+53.34%
Max Drawdown (10Y) Largest decline over 10 years	-65.56%	—	—
Current Drawdown Current decline from peak	-5.36%	-83.58%	+78.22%
Average Drawdown Average peak-to-trough decline	-15.98%	-84.22%	+68.24%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.20%	14.09%	-8.89%

Volatility

REPYY vs. ELVN - Volatility Comparison

The current volatility for Repsol SA (REPYY) is 9.74%, while Enliven Therapeutics Inc. (ELVN) has a volatility of 14.50%. This indicates that REPYY experiences smaller price fluctuations and is considered to be less risky than ELVN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	REPYY	ELVN	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.74%	14.50%	-4.76%
Volatility (6M) Calculated over the trailing 6-month period	25.08%	60.61%	-35.53%
Volatility (1Y) Calculated over the trailing 1-year period	29.25%	82.50%	-53.25%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	28.48%	85.81%	-57.33%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	32.31%	87.95%	-55.64%

Dividends

REPYY vs. ELVN - Dividend Comparison

REPYY's dividend yield for the trailing twelve months is around 4.30%, while ELVN has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
ELVN Enliven Therapeutics Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
REPYY Repsol SA	4.30%	5.69%	8.07%	5.03%	4.22%	2.41%	8.21%	8.35%	2.97%	4.31%	3.89%

Financials

Frequently Asked Questions

Can I hold both REPYY and ELVN in my portfolio?

REPYY and ELVN have a correlation of -0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, REPYY or ELVN?

ELVN has higher volatility (14.50%) compared to REPYY (9.74%). In terms of maximum drawdown, REPYY dropped -65.56% vs ELVN's -98.20%.

Which has better risk-adjusted returns?

REPYY currently has the higher Sharpe Ratio (3.81 vs 0.80), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.